Explore

Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Rapid Read Rapid Read
Researchers Identify Bemnifosbuvir as Potential Treatment for Hepatitis E

Researchers Identify Bemnifosbuvir as Potential Treatment for Hepatitis E

An international team of researchers has identified bemnifosbuvir, a drug currently in trials for hepatitis C, as a promising candidate for treating hepatitis E. The study, published in the journal Gut, involved scientists from Bochum and Heidelberg in Germany and Beijing in China. Bemnifosbuvir belongs to a class of molecules known as nucleotide/nucleoside analogues, which mimic the building blocks of genetic material. The researchers tested approximately 500 compounds using a specially engineered hepatitis E virus that produces a fluorescent signal. This method allowed them to determine whether the virus continued to replicate after treatment. The results showed that bemnifosbuvir effectively stopped the virus from replicating while keeping the treated cells healthy. Follow-up studies in animals confirmed the drug's ability to reduce viral activity and liver inflammation.
Trendline Trendline
AI Revolutionizes Biotech Industry Amidst IT Sector Layoffs

AI Revolutionizes Biotech Industry Amidst IT Sector Layoffs

AI Revolutionizes Biotech Industry Amidst IT Sector Layoffs
Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
Anthropic Acquires Biotech AI Startup Coefficient Bio for $400 Million, Expanding AI in Drug Discovery

Anthropic Acquires Biotech AI Startup Coefficient Bio for $400 Million, Expanding AI in Drug Discovery

Anthropic Acquires Biotech AI Startup Coefficient Bio for $400 Million, Expanding AI in Drug Discovery
Rapid Read Rapid Read
AI-Repurposed Drug MDL-001 Shows Promise Against Multiple Viruses in Lab Studies

AI-Repurposed Drug MDL-001 Shows Promise Against Multiple Viruses in Lab Studies

A drug originally developed for breast cancer, now renamed MDL-001, has shown potential in lab studies to inhibit a variety of viruses, including coronaviruses, RSV, norovirus, and influenza. The drug was identified using an AI platform by Model Medicines, a California-based company. The AI discovered that MDL-001 could target a viral enzyme called RNA-dependent RNA polymerase, crucial for viral replication. This discovery suggests that MDL-001 could be a multipurpose antiviral pill, potentially useful in treating common viral infections and future pandemics. The drug will undergo clinical trials next year to assess its safety and efficacy in humans.
Trendline Trendline
TriNetX and Regeneron Partner to Enhance Drug Discovery with Health Data

TriNetX and Regeneron Partner to Enhance Drug Discovery with Health Data

TriNetX and Regeneron Partner to Enhance Drug Discovery with Health Data
Trendline Trendline
GATC Health's AI Platform Reduces Drug Development Costs with In Silico Models

GATC Health's AI Platform Reduces Drug Development Costs with In Silico Models

GATC Health's AI Platform Reduces Drug Development Costs with In Silico Models
Trendline Trendline
GATC Health Utilizes AI to Reduce Therapeutic Development Costs and Time

GATC Health Utilizes AI to Reduce Therapeutic Development Costs and Time

GATC Health Utilizes AI to Reduce Therapeutic Development Costs and Time
Trendline Trendline
Regeneron and TriNetX Collaborate to Enhance Genomic and Health Data Integration

Regeneron and TriNetX Collaborate to Enhance Genomic and Health Data Integration

Regeneron and TriNetX Collaborate to Enhance Genomic and Health Data Integration
Trendline Trendline
TriNetX and Regeneron Collaborate to Enhance Drug Discovery with Access to 300 Million Patient Health Records

TriNetX and Regeneron Collaborate to Enhance Drug Discovery with Access to 300 Million Patient Health Records

TriNetX and Regeneron Collaborate to Enhance Drug Discovery with Access to 300 Million Patient Health Records
Trendline Trendline
Agilent Technologies Launches BioTek Cytation 9, Enhancing Laboratory Imaging Capabilities

Agilent Technologies Launches BioTek Cytation 9, Enhancing Laboratory Imaging Capabilities

Agilent Technologies Launches BioTek Cytation 9, Enhancing Laboratory Imaging Capabilities